Tevogen R&D Chief Sells 972 Shares, Transactions Total About $6,635
Neal Flomenberg, Tevogen Bio Holdings Inc.'s Chief Scientific Officer and Global R&D Lead, sold 972 shares of common stock between March 10 and March 13, 2026, for roughly $6,635. The sales were executed to cover tax obligations tied to restricted stock units. Separately, Tevogen's board is evaluating a possible one-time special cash dividend conti…